Articles by Cody R. Barnett, MRA Director of Communications
Promising Uveal Melanoma Research Advances
Uveal melanoma, often called ocular melanoma or just eye melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. As is true with other rare subtypes, we know far less about what causes uveal melanoma, how it progresses, and how it can be...
Melanoma Isn't Just Another Skin Cancer
Too many people think that melanoma is just another skin cancer – and in 2005, Daisy Helman was one of them. She had just learned that a lump her father noticed on his arm was actually melanoma. “I just assumed that this wasn’t a big deal. Just cut it out – dad will be fine. Looking back, I was so wrong.”
Antibiotics & Treatment-Resistant Melanoma: A Stressful Subject
Eleonora Leucci, PhD, an MRA-funded investigator at KU Leuven (Belgium) has determined that some antibiotics may be able to slow, or even reverse, treatment resistance that melanoma develops to targeted therapies. If her preliminary findings are verified in the clinic, this would be a potent weapon in the melanoma treatment arsenal and a huge win for patients.
Asking the Tough Questions: Perspectives on Being a Caregiver, Self Care, & Mucosal Melanoma
“Being a caregiver can be the hardest job,” says Patricia Janiak. “Your loved one might be the one going through this – but we’re the ones who have to put on our brave face while always being a step ahead. We’re the ones who call the doctors, ask the tough questions, and when needed, we push the envelope.”
Mark, Stage 4 Melanoma, & a Personalized Vaccine Clinical Trial
The melanoma treatment landscape had dramatically changed in the time since Mark was first diagnosed with melanoma. New options had earned FDA approval and many other approaches were actively being tested in clinical trials. Hear Mark's story with a personalized vaccine made to help train his immune system to fight melanoma cells.
Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma
After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.
For Amanda, Research is Personal
By Cody R. Barnett, MRA Director of Communications | 26 June 2021
For Amanda, melanoma research will always be personal. In addition to her own history – she is very aware that her four children will also always be connected to this disease. “We’ve made some real progress – and that’s great – but we aren’t there yet. My kids now have a history of this, too – and I’m also doing this for them. Discoveries don’t happen by accident – we have to be willing to invest in them.”
Advancing Melanoma Research in Times of Uncertainty
Each year, the annual MRA Scientific Retreat brings hundreds of people from across the melanoma research ecosystem together to exchange ideas, report on scientific progress, celebrate achievements, and mourn the losses. In these ways, the 2021 Retreat was no different.
Separating Hope From Hype in Melanoma Research
In the last decade alone 13 therapeutic approaches have earned FDA approval giving patients, families, and clinicians new tools to treat melanoma. But there can be a fine line between hope and hype, especially today when news — both true and inflated — travels instantly via the internet and social media.
Firming the Foundation: Pathology, Rare Melanomas, and Moving the Field Forward
When Dr. Priyadharsini Nagarajan talks about her work at MD Anderson Cancer Center, her energy and excitement could light up any room. That’s because Dr. Nagarajan – a pathologist who specializes in skin (called a ‘dermatopathologist’) – sees her work as critical to creating a firm foundation for all subsequent...
About the Author
Cody R. Barnett, MRA Director of Communications
Cody R. Barnett joined the Melanoma Research Alliance (MRA) as Director of Communications in August of 2017. He works to develop and cultivate strategies, messages, and stories that propel MRA’s mission forward. Cody is responsible for media relations, web and social marketing, publications and materials development, and organizational branding. He is committed to using the power of visual, verbal, and written communications to promote MRA as a powerful force for advancing melanoma research.
Before joining the Melanoma Research Alliance, Cody served as Director of Communications at AIDS United, where he directed all internal, public, member, and online communications for the national HIV-focused organization. Previous to this, he managed digital communications for the Robert Wood Johnson Foundation’s Aligning Forces for Quality (AF4Q) initiative.
Cody earned his Master of Public Health (MPH), concentrating in health policy, from The George Washington University Milken Institute School of Public Health in 2013 and a Bachelor of Arts in political science from York College of Pennsylvania.